Tuberculosis treatment unmasking leprosy: management of drug-resistant tuberculosis and leprosy co-infection.

Printer-friendly version
TitleTuberculosis treatment unmasking leprosy: management of drug-resistant tuberculosis and leprosy co-infection.
Publication TypeJournal Article
AuthorsKama G, Huang GKL, Taune M, Arura R, Morris L, Kombuk B, Marome A, O'Brien DP
Abbrev. JournalPublic Health Action
JournalPublic health action
Year of Publication2019
Volume9
IssueSuppl 1
PaginationS83-S85
Publication Languageeng
Abstract

Co-infection with tuberculosis (TB) and leprosy is thought to occur infrequently, but has been reported in settings highly endemic for both infectious diseases. We report for the first time a case where treatment for multidrug-resistant TB (MDR-TB) led to the 'unmasking' of clinically silent leprosy through the precipitation of a type-1 immunological reaction. Current treatment regimens for MDR-TB may contain a number of drugs, such as levo-floxacin and clofazimine, which also have activity against M. leprae. A treatment regimen containing drugs active against both mycobacterial species may be used to achieve cure. Individual considerations on drug-drug interactions, potential additive toxicities and other comorbidities should be taken into account.

PubMed URL

http://www.ncbi.nlm.nih.gov/pubmed/31579656?dopt=Abstract

DOI10.5588/pha.18.0104
PubMed Central IDPMC6735462